Vanda Pharmaceuticals, Inc.

NASDAQ: VNDA
$9.90
+$0.23 (+2.3%)
Real time price as of March 31, 2020 1:35 pm EDT
Vanda Pharma shares dropped early to start out the week after the frim announced that it received a Complete Response Letter from the FDA.
Chris Lange
The top analyst upgrades, downgrades and initiations seen on Thursday included Allstate, Corning, DexCom, Lam Research, On Deck, Qualcomm, Spotify, Western Digital and Whiting Petroleum.
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Thursday included AT&T, Caterpillar, Dollar General, Electronic Arts, Etsy, Facebook, Spirit Airlines, Tesla and Xilinx.
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Wednesday included DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap and Vishay.
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Tuesday included Abbott Laboratories, Apple, Apptio, Cheniere Energy, First Solar, Kratos Defense & Security Solutions, Smartsheet,...
Jon C. Ogg
Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis.
Chris Lange
The top analyst upgrades, downgrades and other research calls from Monday include AMD, Chevron, GM, Intel, Merck, Nokia and Under Armour.
Jon C. Ogg
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess and Western Digital.
Jon C. Ogg
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Lee Jackson
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
Lee Jackson
The top analyst upgrades, downgrades and initiations seen on Thursday morning include American Express, Encana, Petrobras, Raytheon, Tesla and Walgreens.
Jon C. Ogg
Given the fact that insider sales windows are closing fast as third-quarter earnings are imminent, it is pretty easy to understand the spike in selling volume we saw this past week.
Lee Jackson
Once again insiders were making transactions that may be getting done now in an effort to beat the closure of trading windows as third-quarter earnings season approaches.
Lee Jackson
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Chris Lange
One interesting tidbit to this week's insider trading was all the energy stocks that are showing up. It is clear many insiders feel the bottom is close and now is the time to buy shares.
Lee Jackson